HER3

BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

Retrieved on: 
星期一, 五月 6, 2024
Drug discovery, CLDN6, Fast Track, Lung cancer, AI, CRC, Webcast, PDAC, BioNTech, Pfizer, Genentech, Prevalence, Corporation, Vaccination, Deutsche Bundesbank, Influenza, Food, Roche, Omicron, ADC, Toxicity, Tumor antigen, Messenger, NSCLC, Telephone, Combination therapy, Pfizer–BioNTech COVID-19 vaccine, Patient, Safety, HER3, Pembrolizumab, RNA, PD-1, Docetaxel, Digital, DNA, Observational study, Neoplasm, First, Investigational New Drug, EDT, Recurrence, PD-L1, Antigen, Bank statement, Breakthrough therapy, Uridine, COVID-19, Pharmaceutical industry

MAINZ, Germany, May 6, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for the three months ended March 31, 2024, and provided an update on its corporate progress.

Key Points: 
  • 1 Calculated applying the average foreign exchange rate for the three months ended March 31, 2024, as published by the German Central Bank (Deutsche Bundesbank).
  • BioNTech is now focused on preparing for variant strain vaccine adaptation to be ready for commercial launch ahead of the upcoming 2024/2025 vaccination season, pending approvals.
  • In March, BioNTech announced that Annemarie Hanekamp will be joining the Company’s Management Board as Chief Commercial Officer on July 1, 2024.
  • Second Quarter 2024 Financial Results and Corporate Update: August 5, 2024
    Innovation Series (Digital & AI Day): October 1, 2024
    BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, May 6, 2024, at 8:00 a.m. EDT (2:00 p.m. CEST) to report its financial results and provide a corporate update for three months ended March 31, 2024.

Data Presented at AACR 2024 Showcase Precede Biosciences’ Power to Impact Precision Medicine from a Simple Blood Test

Retrieved on: 
星期三, 四月 10, 2024
MET, Hospital, HER2, HER3, Breast, MD, CEACAM5, Patient, CLDN18, Lung, Health, Biology, AACR, EGFR, Massachusetts General Hospital, Plasma, Pharmaceutical industry

Data further underscore potential to inform therapy selection for antibody drug conjugates and other target-directed therapies across breast, lung, and gastro-esophageal cancers

Key Points: 
  • Data further underscore potential to inform therapy selection for antibody drug conjugates and other target-directed therapies across breast, lung, and gastro-esophageal cancers
    Targets revealed from a single 1mL plasma sample include B7H4, CEACAM5, CLDN18, EGFR, HER2, HER3, MET, NECTIN4, and TROP2
    BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared three scientific poster presentations from the 2024 American Association for Cancer Research (AACR) Annual Meeting.
  • “The data presented at AACR 2024 add to the growing body of evidence supporting our platform’s unique ability to provide genome-wide insight into the activation status of therapeutic targets, pathways, and resistance mechanisms, all from a simple blood draw,” said Carl Barrett, Chief Scientific Officer of Precede Bio.
  • “As such, we have a significant opportunity to better inform patient selection and enable indication expansion for the many promising agents addressing these targets and pathways with our platform.”
    “Our study highlights the need for new approaches to profile the biology of gastro-esophageal adenocarcinoma, an aggressive disease in which patients can progress quickly,” said Samuel Klempner, MD, medical oncologist at Massachusetts General Hospital and senior author for the abstract on gastro-esophageal cancers.
  • “Precede Bio’s liquid biopsy platform could represent an important advance enabling informed treatment decisions and personalized patient care throughout the cancer journey for this difficult-to-treat cancer.”
    Precede Bio’s posters from AACR 2024 can be found in the presentations section of the company website and are linked directly below:

Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines

Retrieved on: 
星期三, 四月 24, 2024
Biotechnology, Health, Oncology, Clinical Trials, Idiopathic pulmonary fibrosis, PPF, ATS, HER3, IPF, Conference, Matrix, Entrepreneurship, ADC, Senior, Pulmonary fibrosis, Patient, Associate, Neoplasm, Symbiosis, Toxicity, American Thoracic Society, Series, Cancer, Spacecraft

Endeavor BioMedicines, Inc. (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the closing of a $132.5 million Series C financing, including the conversion of a $5 million convertible instrument.

Key Points: 
  • Endeavor BioMedicines, Inc. (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the closing of a $132.5 million Series C financing, including the conversion of a $5 million convertible instrument.
  • Endeavor plans to initiate a Phase 2b trial in patients with IPF and in parallel a cohort of patients with PPF in 2024.
  • “Endeavor BioMedicines’ novel drug candidates have the potential to disrupt the underlying mechanisms that cause serious, life-threatening diseases,” said Karan Takhar, Senior Managing Director at Matrix, who will join Endeavor BioMedicines’ Board of Directors as part of the Series C financing.
  • “I look forward to collaborating with Endeavor BioMedicines’ executive team and other members of the board to support the company’s clinical execution as it pursues significant milestones in 2024 and beyond.”

Non-Small-Cell Lung Cancer (NSCLC) Pipeline Landscape Report 2024: Comprehensive Insights About 100+ Companies and 120+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
星期三, 三月 6, 2024
Pharmaceutical, Health, Oncology, Clinical Trials, Therapy, NSCLC, Acquisition, Neoplasm, Cancer, Non-small-cell lung cancer, Messenger, NRG1, News, Pertuzumab, Epitope, PD-1, Discovery, Antibody, HER2, Lung cancer, HER3, Immunoglobulin G, Trastuzumab, Clinical trial, Immunology, NDA, ERBB2, DNA, Pharmaceutical industry

This report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape.
  • A detailed picture of the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape is provided which includes the disease overview and Non-Small-Cell Lung cancer (NSCLC) treatment guidelines.
  • The assessment part of the report embraces, in depth Non-Small-Cell Lung cancer (NSCLC) commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Non-Small-Cell Lung cancer (NSCLC) R&D.

Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
星期二, 三月 5, 2024
Patient, HER3, AACR, ADC

BOSTON, March 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical need, today announced that it will present preclinical proof-of-concept data for its differentiated HER3-targeting antibody-drug conjugate (ADC) program in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.

Key Points: 
  • "We are excited to share preclinical proof-of-concept data for our HER3-ADC program.
  • "At AACR, we plan to share preclinical proof-of-concept data highlighting our progress towards the development of a differentiated HER3-ADC.
  • We look forward to nominating a development candidate this year and to the advancement of our HER3-ADC program toward the clinic, with the goal of improving patient outcomes."
  • Details of the poster presentation at AACR 2024 are as follows:

Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024

Retrieved on: 
星期二, 三月 5, 2024
SAN, Neoplasm, VISTA, AACR, Lung cancer, Triple-negative breast cancer, HER3, Patient, Poster, Pharmaceutical industry

HMBD-001 is shown to potently block oncogenic signaling driven by HER3 mutations and could offer significant clinical benefit for patients with HER3 mutations across cancer types.

Key Points: 
  • HMBD-001 is shown to potently block oncogenic signaling driven by HER3 mutations and could offer significant clinical benefit for patients with HER3 mutations across cancer types.
  • The poster will highlight that more than 80% tumor growth inhibition is seen across multiple preclinical models with common HER3 mutations.
  • We look forward to discussing our recent advancements with the oncology research community at AACR," said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer, Hummingbird Bioscience.
  • Hummingbird Bioscience is recruiting patients with aberrant HER3 signaling, which includes selected HER3 mutations, in the company's ongoing Phase Ib trial (NCT05919537).

Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Retrieved on: 
星期五, 十二月 22, 2023
Biotechnology, Pharmaceutical, Health, Oncology, MSD, Senior, Food, Leukopenia, Priority review, Hypokalemia, Daiichi Sankyo, FDA, Breakthrough therapy, PDUFA, EGFR, ILD, Anemia, Fatigue, HER3, Neutropenia, MD, Biologics license application, Recurrence, Patritumab, Weakness, Thrombocytopenia, Merck & Co., DXD, Patient, Safety, Medicine, MRK, ADC, NSCLC, BLA, Pharmaceutical industry

The Prescription Drug User Fee Act (PDUFA) date, the FDA action date for their regulatory decision, is June 26, 2024.

Key Points: 
  • The Prescription Drug User Fee Act (PDUFA) date, the FDA action date for their regulatory decision, is June 26, 2024.
  • The Priority Review follows receipt of Breakthrough Therapy Designation granted by the FDA in December 2021.
  • RTOR allows the FDA to review components of an application before submission of the complete application.
  • Twelve patients (5.3%) had confirmed treatment-related interstitial lung disease (ILD) as determined by an independent adjudication committee.

Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of Directors

Retrieved on: 
星期二, 十二月 19, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Sale, HER3, Pharming, Therapy, Cancer, Endeavour, Neoplasm, IPO, Patient, Corporate development, Fibrosis, H.I.G. Capital, Management

Endeavor BioMedicines, a clinical-stage company developing therapies for fibrotic disease and oncology, announced that the company has appointed Enoch Kariuki, Pharm.D.

Key Points: 
  • Endeavor BioMedicines, a clinical-stage company developing therapies for fibrotic disease and oncology, announced that the company has appointed Enoch Kariuki, Pharm.D.
  • to the Endeavor BioMedicines Board of Directors.
  • Kariuki is an excellent addition to our esteemed board of directors, who are helping us advance our pipeline of therapies for patients with fibrosis and cancer,” said John Hood, Ph.D., co-founder, CEO and chairman, Endeavor BioMedicines.
  • “Endeavor BioMedicines’ pipeline of differentiated therapeutic options has the potential to make a significant difference in the treatment of fibrotic lung diseases as well as cancer,” said Dr. Kariuki.

BostonGene to Present Research with Leading Cancer Centers at Society for Immunotherapy of Cancer’s 2023 Annual Meeting

Retrieved on: 
星期三, 十一月 1, 2023
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Research, Artificial Intelligence, Genetics, Science, Clinical Trials, RNA-Seq, NSCLC, Progression-free survival, IHC, ICIS, RNA, HPV, ICI, HER2, Head, SITC, San Diego Convention Center, Immunotherapy, ADC, HER3, Pinsly Railroad Company, Annual general meeting, Classification, Tumor microenvironment, Overalls, Society, Cancer, TME, Patient, Gene expression, Potential, Neck, Vaccine, HNSCC

BostonGene , a leading provider of AI-driven molecular and immune profiling solutions, today announced the Company will present four posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023 at the San Diego Convention Center in San Diego, CA.

Key Points: 
  • BostonGene , a leading provider of AI-driven molecular and immune profiling solutions, today announced the Company will present four posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023 at the San Diego Convention Center in San Diego, CA.
  • BostonGene will also exhibit at booth 639.
  • This study underscores the importance of considering a patient’s HPV status when assessing mechanisms associated with ICI response in HNSCC.
  • To learn more or to schedule a meeting with BostonGene during SITC, please contact Maria Proia at [email protected] .

Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)

Retrieved on: 
星期四, 十月 19, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Neoplasm, HER2, Fibrosis, Entrepreneurship, Engineering, ADC, HER3, Spacecraft, NRG1, Safety, Patient, Therapeutic index, Pharmaceutical industry, Fine chemical, Endeavour

Hummingbird Bioscience (“Hummingbird Bio”), a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Endeavor BioMedicines (“Endeavor”), a clinical-stage company targeting the drivers of fibrosis and oncology, today announced that Endeavor has acquired exclusive worldwide rights to Hummingbird Bio’s antibody-drug conjugate (ADC), HMBD-501.

Key Points: 
  • Hummingbird Bioscience (“Hummingbird Bio”), a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Endeavor BioMedicines (“Endeavor”), a clinical-stage company targeting the drivers of fibrosis and oncology, today announced that Endeavor has acquired exclusive worldwide rights to Hummingbird Bio’s antibody-drug conjugate (ADC), HMBD-501.
  • The license agreement provides Endeavor with exclusive rights to HMBD-501, a next-generation HER3-targeted ADC with an exatecan payload that has been optimized for safety and efficacy.
  • Under the terms of the license, Hummingbird Bio will be eligible to receive upfront and milestone payments up to $430 million, plus royalties on net sales.
  • “We are pleased to license HMBD-501 to the experienced Endeavor team to bring the molecule into the clinic and a step closer to benefiting patients.”